Position in MRK
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$630,421
+$230,940 QoQ
Shares Held
4,906
+47.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.60%
of 13F equity value
Holder Rank
#2,499
of 3,769 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 90%
Shared 8%
None 2%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Lynx Investment Advisory holds $4,458,205 across 7 Drug Manufacturers - General names. MRK ranks #4 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
59,638 | $1,436,081 | |
| 2 | ABBV |
AbbVie Inc.
|
2,938 | $739,317 | |
| 3 | JNJ |
Johnson & Johnson
|
2,594 | $658,796 | |
| 4 | MRK |
Merck & Co., Inc.
This page
|
4,906 | $630,421 | |
| 5 | AZN |
Astrazeneca PLC
|
2,144 | $406,544 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,540 | $319,212 | |
| 7 | NVS |
Novartis AG
|
1,709 | $267,834 |
All Filings in MRK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $630,421 | 4,906 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $399,481 | 3,321 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $398,829 | 3,789 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $333,368 | 3,972 | Shares | Other | 2025-11-06 | |
| 2025-06-30 | $314,422 | 3,972 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $305,990 | 3,409 | Shares | Sole | 2025-06-16 | |
| 2024-12-31 | $304,904 | 3,065 | Shares | Other | 2025-02-11 | |
| 2024-09-30 | $332,616 | 2,929 | Shares | Other | 2024-11-04 | |
| 2024-06-30 | $279,787 | 2,260 | Shares | Other | 2024-07-09 | |
| No filing history on record for this holder in this stock. | ||||||